Literature DB >> 17953445

Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.

Lisa M Kaminskas1, Ben J Boyd, Peter Karellas, Scott A Henderson, Michael P Giannis, Guy Y Krippner, Christopher J H Porter.   

Abstract

Tritium-labeled poly- l-lysine dendrimers displaying 8 or 16 surface lysines have been capped with benzene sulfonate (BS), benzene disulfonate (BDS), or succinate (Succ) groups, and the intravenous pharmacokinetics and disposition profiles of the resulting dendrimers (Lys(8)(BS)(16), Lys(16)(BS)(32), Lys(16)(BDS)(32), Lys(16)(Succ)(32)) have been evaluated. Lys(16)(Succ)(32) was rapidly removed from the plasma primarily via renal elimination. Lys(16)(BS)(32) and Lys(16)(BDS)(32) were opsonized, resulting in more prolonged plasma elimination kinetics and increased uptake by the liver. Data obtained at higher doses suggested some evidence of nonlinear pharmacokinetics. Lys(8)(BS)(16) had reduced affinity for plasma proteins and was cleared more rapidly than the larger Lys(16)(BS)(32) or Lys(16)(BDS)(32) dendrimers. Lys(8)(BS)(16) and Lys(16)(BS)(32) were metabolized in vivo, resulting in the production of a low molecular weight species (possibly the cleavage product Lys(BS) (2)) that was extensively renally eliminated and accounted for almost all of the radioactivity recovered in urine ( approximately 20-45% of administered (3)H). In contrast, only 3-5% of the administered (3)H was recovered in the urine of rats administered Lys(16)(BDS)(32), suggesting increased resistance to in vivo degradation. The plasma clearance, distribution, and metabolic profiles of lysine dendrimers are therefore significantly influenced by the structure and charge of the capping groups. In particular, larger arylsulfonate-capped lysine dendrimers are rapidly opsonized and initially cleared from the plasma by the reticuloendothelial organs. The degree of metabolism is subsequently dictated by the nature of the surface capping group with BDS surfaces seemingly more resistant to breakdown. In contrast, smaller arylsulfonate-capped dendrimers are less readily opsonized and phagocytozed but are metabolically labile, and succinate-capped dendrimers are rapidly eliminated by the kidneys.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17953445     DOI: 10.1021/mp070047s

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  10 in total

Review 1.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

2.  Structure activity relationship of dendrimer microbicides with dual action antiviral activity.

Authors:  David Tyssen; Scott A Henderson; Adam Johnson; Jasminka Sterjovski; Katie Moore; Jennifer La; Mark Zanin; Secondo Sonza; Peter Karellas; Michael P Giannis; Guy Krippner; Steve Wesselingh; Tom McCarthy; Paul R Gorry; Paul A Ramsland; Richard Cone; Jeremy R A Paull; Gareth R Lewis; Gilda Tachedjian
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

Review 3.  Effects of nanomaterial physicochemical properties on in vivo toxicity.

Authors:  Kristin L Aillon; Yumei Xie; Nashwa El-Gendy; Cory J Berkland; M Laird Forrest
Journal:  Adv Drug Deliv Rev       Date:  2009-04-20       Impact factor: 15.470

4.  Recent advances in targeted drug delivery approaches using dendritic polymers.

Authors:  Jason Bugno; Hao-jui Hsu; Seungpyo Hong
Journal:  Biomater Sci       Date:  2014-12-11       Impact factor: 6.843

5.  Sunflower Polymers for Folate-Mediated Drug Delivery.

Authors:  Christine E Wang; Hua Wei; Nicholas Tan; Andrew J Boydston; Suzie H Pun
Journal:  Biomacromolecules       Date:  2015-12-10       Impact factor: 6.988

Review 6.  Tweaking dendrimers and dendritic nanoparticles for controlled nano-bio interactions: potential nanocarriers for improved cancer targeting.

Authors:  Jason Bugno; Hao-Jui Hsu; Seungpyo Hong
Journal:  J Drug Target       Date:  2015       Impact factor: 5.121

Review 7.  Multivalent polymers for drug delivery and imaging: the challenges of conjugation.

Authors:  Mallory A van Dongen; Casey A Dougherty; Mark M Banaszak Holl
Journal:  Biomacromolecules       Date:  2014-08-22       Impact factor: 6.988

Review 8.  Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs.

Authors:  Ludger Johannes; Marco Lucchino
Journal:  Nucleic Acid Ther       Date:  2018-06       Impact factor: 5.486

9.  Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors.

Authors:  Hemant Sarin; Ariel S Kanevsky; Haitao Wu; Alioscka A Sousa; Colin M Wilson; Maria A Aronova; Gary L Griffiths; Richard D Leapman; Howard Q Vo
Journal:  J Transl Med       Date:  2009-06-23       Impact factor: 5.531

10.  dendPoint: a web resource for dendrimer pharmacokinetics investigation and prediction.

Authors:  Lisa M Kaminskas; Douglas E V Pires; David B Ascher
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.